Insulin Under the BPCIA: Opportunities and Obstacles
April 22, 2020
By: Ted Mathias
Biosimilar Development
Axinn partner Ted Mathias authored the Biosimilar Development article, "Insulin Under the BPCIA: Opportunities and Obstacles."
Click here to access the article.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
ACI 12th Annual Summit for Women Leaders in Life Sciences Law
Speaking Engagement
Intellectual Property
National LGBTQ+ Bar Association Lavender Law Conference and Career Fair 2025
Sponsorship
National Bar Association 100th Annual Convention and Exhibits
Sponsorship
Antitrust
Keeping Pace: Updates in Cartel Enforcement
Webinar
Antitrust
New Incentives, New Rewards: What You Need to Know About the Antitrust Division’s First-Ever Whistleblower Rewards Program
Axinn Viewpoints
Antitrust
Informa Antitrust Midwest
Speaking Engagement
GCR Live: Law Leaders Europe 2025
Speaking Engagement
Antitrust
How I Made Partner: 'Show Up and Build Rapport With Colleagues and Clients,' Says Michael O'Mara of Axinn Veltrop & Harkrider
Media Mentions
Antitrust
Axinn Counsel Rebecca Clegg Named 2025 MCCA Rising Star
Awards & Recognitions
Intellectual Property
Chambers Merger Control 2025 Guide
Byline Articles
Antitrust